



HOUSE BILL 1043: 2020 COVID-19 Recovery Act, Sec. 3.3(22): Duke University Human Vaccine Institute

2019-2020 General Assembly

Committee:		Date:	October 22, 2020
Introduced by:		Prepared by:	Theresa Matula
Analysis of:	Sec. 3.3(22) of S.L. 2020-4, as amended		Legislative Analyst

OVERVIEW: Section 3.3(22) of S.L. 2020-4, requires the Office of State Budget and Management to allocate \$15 million of the funds appropriated from the Coronavirus Relief Fund to the Duke University Human Vaccine Institute (DHVI) of the Duke University School of Medicine to develop a safe and effective COVID-19 vaccine. This initial allocation became effective May 4, 2020.

Section 1.2 of S.L. 2020-97 amended Section 3.3(22) of S.L. 2020-4, to increase the allocation from \$15 million to \$17 million and to require the DHVI to develop both (i) a safe and effective COVID-19 vaccine and (ii) rapid, low-cost COVID-19 testing for active infections. This additional allocation and requirement became effective September 4, 2020.

Jeffrey Hudson
Director

H1043-SMSH-110(sI)-v-12

Legislative Analysis
Division
919-733-2578